AJMC articleshttps://www.ajmc.com/newsAJMC articles© 2026 MJH Life Sciences™ and AJMC. All rights reserved.Tue, 11 Aug 2026 03:19:49 +00005en-us14447https://www.ajmc.com/newshttps://www.ajmc.com/logo.webphttps://www.ajmc.com/view/access-coverage-and-final-reflections-on-managing-alzheimer-s-disease-agitationhttps://www.ajmc.com/view/access-coverage-and-final-reflections-on-managing-alzheimer-s-disease-agitation<![CDATA[In the final episode, 'Access, Coverage, and Final Reflections on Managing Alzheimer's Disease Agitation,' the panelists explored the following critical questions: How has insurance coverage been with the Food and Drug Administration (FDA)-approved therapies for Alzheimer's disease agitation? What are best practices in working with insurance providers to get coverage for patients? ]]>Mon, 10 Aug 2026 21:25:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/choosing-between-approved-therapies-differentiation-sequencing-and-black-box-warning-navigation-in-alzheimer-s-disease-agitationhttps://www.ajmc.com/view/choosing-between-approved-therapies-differentiation-sequencing-and-black-box-warning-navigation-in-alzheimer-s-disease-agitation<![CDATA[In 'Choosing Between Approved Therapies: Differentiation, Sequencing, and Black Box Warning Navigation in Alzheimer's Disease Agitation,' the expert neurologists examined the following critical questions: In your practice, how are you differentiating antipsychotic therapies from dextromethorphan-bupropion for patients with Alzheimer's disease agitation? With the introduction of 2 Food and Drug Administration (FDA)-approved therapies in the last few years, how are you sequencing treatments in patients with Alzheimer's disease agitation? How are you navigating black box warnings with certain therapies? ]]>Mon, 10 Aug 2026 21:24:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/comparing-the-two-approved-therapies-dextromethorphan-bupropion-and-brexpiprazole-in-alzheimer-s-disease-agitationhttps://www.ajmc.com/view/comparing-the-two-approved-therapies-dextromethorphan-bupropion-and-brexpiprazole-in-alzheimer-s-disease-agitation<![CDATA[In this episode, 'Comparing the Two Approved Therapies: Dextromethorphan-Bupropion and Brexpiprazole in Alzheimer's Disease Agitation,' the expert neurologists explored the following question: What were the key safety and efficacy results that led to its approval and how do they compare with brexpiprazole's?]]>Mon, 10 Aug 2026 21:22:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/brexpiprazole-and-dextromethorphan-bupropion-mechanisms-of-action-and-key-clinical-trial-data-for-approved-alzheimer-s-disease-agitation-therapieshttps://www.ajmc.com/view/brexpiprazole-and-dextromethorphan-bupropion-mechanisms-of-action-and-key-clinical-trial-data-for-approved-alzheimer-s-disease-agitation-therapies<![CDATA[In 'Brexpiprazole and Dextromethorphan-Buproprion: Mechanisms of Action and Key Clinical Trial Data for Approved Alzheimer's Disease Agitation Therapies,' the expert neurologists examined the following critical questions: Brexpiprazole was approved by the Food and Drug Administration (FDA) in 2023 and dextromethorphan/buproprion in 2026 for the treatment of Alzheimer's disease agitation. What are the mechanisms of action of these therapies? What were the key safety and efficacy results seen in the clinical trials?]]>Mon, 10 Aug 2026 21:20:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/traditional-pharmacologic-therapies-for-alzheimer-s-disease-agitation-mechanisms-evidence-and-adverse-eventshttps://www.ajmc.com/view/traditional-pharmacologic-therapies-for-alzheimer-s-disease-agitation-mechanisms-evidence-and-adverse-events<![CDATA[In this episode, 'Traditional Pharmacologic Therapies for Alzheimer's Disease Agitation: Mechanisms, Evidence, and Adverse Events,' the expert neurologists explored the following questions: What are the traditional therapies such as antipsychotics used in the management of patients with Alzheimer's disease agitation and their respective mechanisms of action? What has the data demonstrated with these therapies? What are the adverse events seen with these therapies? When are you utilizing dose reductions with these therapies? ]]>Mon, 10 Aug 2026 21:18:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/non-pharmacologic-approaches-to-alzheimer-s-disease-agitation-interventions-best-practices-and-case-exampleshttps://www.ajmc.com/view/non-pharmacologic-approaches-to-alzheimer-s-disease-agitation-interventions-best-practices-and-case-examples<![CDATA[In 'Non-Pharmacologic Approaches to Alzheimer's Disease Agitation: Interventions, Best Practices, and Case Examples,' the expert neurologists examined the following critical questions: Before we get into the medications used to treat Alzheimer's disease agitation, what are the non-pharmacologic options and their respective roles? What are best practices for educating patients and caregivers on these and some case examples? ]]>Mon, 10 Aug 2026 21:16:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/closing-the-recognition-gap-underdiagnosis-patient-education-and-treatment-goals-in-alzheimer-s-disease-agitationhttps://www.ajmc.com/view/closing-the-recognition-gap-underdiagnosis-patient-education-and-treatment-goals-in-alzheimer-s-disease-agitation<![CDATA[In this episode, 'Closing the Recognition Gap: Underdiagnosis, Patient Education, and Treatment Goals in Alzheimer's Disease Agitation,' the expert neurologists explored the following questions: Do you believe that Alzheimer's disease agitation is currently underdiagnosed? How are you educating patients and families? What are the treatment goals for patients with Alzheimer's disease agitation?]]>Mon, 10 Aug 2026 21:10:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/the-burden-of-alzheimer-s-disease-agitation-impact-on-patients-caregivers-and-quality-of-lifehttps://www.ajmc.com/view/the-burden-of-alzheimer-s-disease-agitation-impact-on-patients-caregivers-and-quality-of-life<![CDATA[In 'The Burden of Alzheimer's Disease Agitation: Impact on Patients, Caregivers, and Quality of Life,' the expert neurologists examined the following critical questions: What is the impact that Alzheimer's disease agitation has on patients, as well as their caregivers, and what is the necessary education? How can it impact quality of life and impact families? ]]>Mon, 10 Aug 2026 21:05:36 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/senate-unveils-sweeping-bill-to-reform-340b-drug-programhttps://www.ajmc.com/view/senate-unveils-sweeping-bill-to-reform-340b-drug-program<![CDATA[Bipartisan Senate bill would codify 340B patient rules, end rebate model, boost oversight—as CMS separately proposes deep Medicare 340B payment cuts.]]>Mon, 10 Aug 2026 20:52:05 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/readable-consent-forms-could-boost-trial-enrollment-oyepeju-abioye-akintola-md-mschttps://www.ajmc.com/view/readable-consent-forms-could-boost-trial-enrollment-oyepeju-abioye-akintola-md-msc<![CDATA[Oyepeju Abioye-Akintola, MD, MSc explains how the Protocol &amp; People initiative revealed unreadable consent forms as a fixable barrier to clinical and equitable trial enrollment.]]>Mon, 10 Aug 2026 20:49:24 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/upmc-health-plan-earns-highest-member-satisfaction-scores-in-pennsylvania-from-jd-powerhttps://www.ajmc.com/view/upmc-health-plan-earns-highest-member-satisfaction-scores-in-pennsylvania-from-jd-power<![CDATA[UPMC Health Plan has earned the highest member satisfaction scores for Pennsylvania.]]>Mon, 10 Aug 2026 19:23:35 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/occupational-triggers-chronic-hand-eczema-spanish-cohorthttps://www.ajmc.com/view/occupational-triggers-chronic-hand-eczema-spanish-cohort<![CDATA[A retrospective study of 76 patients at a Spanish allergy clinic found occupational exposure suspected in more than half of chronic hand eczema cases, with patch testing tying most sensitizations to preservatives, nickel, and rubber accelerants.]]>Mon, 10 Aug 2026 18:03:16 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/jak-inhibitor-hesitancy-and-step-therapy-in-pediatric-alopecia-areata-brittany-craiglow-mdhttps://www.ajmc.com/view/jak-inhibitor-hesitancy-and-step-therapy-in-pediatric-alopecia-areata-brittany-craiglow-md<![CDATA[Brittany G. Craiglow, MD, FAAD, discusses JAK inhibitor hesitancy in pediatric alopecia areata, boxed warnings, and why step therapy falls short. ]]>Mon, 10 Aug 2026 18:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/gene-therapy-for-wet-amd-near-an-inflection-point-arshad-khanani-mdhttps://www.ajmc.com/view/gene-therapy-for-wet-amd-near-an-inflection-point-arshad-khanani-md<![CDATA[Arshad Khanani, MD, explains why gene therapy for wet age-related macular degeneration (AMD) is close to becoming a real-world option for the masses.]]>Mon, 10 Aug 2026 17:07:19 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/lipoprotein-a-an-faq-on-awareness-risk-and-screening-gapshttps://www.ajmc.com/view/lipoprotein-a-an-faq-on-awareness-risk-and-screening-gaps<![CDATA[Although new guidelines call for universal screening, most Americans with elevated Lp(a) still don't know their number.]]>Mon, 10 Aug 2026 15:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/severe-eczema-more-than-doubles-shingles-riskhttps://www.ajmc.com/view/severe-eczema-more-than-doubles-shingles-risk<![CDATA[A large UK cohort study found atopic dermatitis raises the risk of shingles by 28%, with the steepest risk in severe disease and younger adults.]]>Mon, 10 Aug 2026 13:14:45 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/potentially-inappropriate-medication-use-following-hospital-discharge-among-medicare-beneficiarieshttps://www.ajmc.com/view/potentially-inappropriate-medication-use-following-hospital-discharge-among-medicare-beneficiaries<![CDATA[Despite financial incentives for Medicare Advantage (MA) plans to reduce potentially inappropriate medication use post hospitalization, this study found that MA does not provide a clear advantage over traditional Medicare.]]>Mon, 10 Aug 2026 13:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/reimbursement-and-geography-as-barriers-to-car-t-accesshttps://www.ajmc.com/view/reimbursement-and-geography-as-barriers-to-car-t-access<![CDATA[Dr. Graff details how rural geography and unfavorable payer reimbursement compound to limit which community oncology practices can safely and sustainably offer T-cell engaging therapies.]]>Mon, 10 Aug 2026 12:05:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/car-t-therapy-access-unmet-needs-and-geographic-gapshttps://www.ajmc.com/view/car-t-therapy-access-unmet-needs-and-geographic-gaps<![CDATA[Debra Patt and Tara Graff open this Insights series by examining why CAR T-cell therapy access remains geographically concentrated, drawing parallels to earlier waves of specialized cancer treatment adoption.]]>Mon, 10 Aug 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/-20-billion-national-strategy-aims-to-close-the-women-s-health-gaphttps://www.ajmc.com/view/-20-billion-national-strategy-aims-to-close-the-women-s-health-gap<![CDATA[A new $20 billion national strategy targets long-standing gaps in women's health research, care, and funding.]]>Sun, 09 Aug 2026 16:17:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/earlier-cancer-screening-could-ease-medicaid-costs-anuraag-r-kansal-phdhttps://www.ajmc.com/view/earlier-cancer-screening-could-ease-medicaid-costs-anuraag-r-kansal-phd<![CDATA[July AJMC author Anuraag R. Kansal, PhD, explains how metastatic cancer diagnoses drive Medicaid spending and why earlier screening could lower costs.]]>Sun, 09 Aug 2026 16:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/science-fiction-made-real-kerry-rogers-md-on-how-car-t-workshttps://www.ajmc.com/view/science-fiction-made-real-kerry-rogers-md-on-how-car-t-works<![CDATA[Prior to receiving CAR T-cell therapy, patients undergo lymphodepletion chemotherapy, explained Kerry Rogers, MD, The James.]]>Sat, 08 Aug 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/trends-and-disparities-in-high-risk-nonsteroidal-anti-inflammatory-drug-utilizationhttps://www.ajmc.com/view/trends-and-disparities-in-high-risk-nonsteroidal-anti-inflammatory-drug-utilization<![CDATA[High-risk nonsteroidal anti-inflammatory drug use declined modestly in Virginia during the COVID-19 pandemic but remained prevalent from 2019 to 2021. Demographic disparities reveal distinct opportunities for targeted deprescribing interventions.]]>Fri, 07 Aug 2026 19:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/smartwatch-study-links-midlife-to-rising-nighttime-awakenings-in-womenhttps://www.ajmc.com/view/smartwatch-study-links-midlife-to-rising-nighttime-awakenings-in-women<![CDATA[New smartwatch data show women's nighttime awakenings jump sharply at midlife—far more than men's—hinting at a menopause-linked sleep shift.]]>Fri, 07 Aug 2026 18:55:26 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/fda-approves-gwyn-lo-a-new-low-dose-contraceptive-patchhttps://www.ajmc.com/view/fda-approves-gwyn-lo-a-new-low-dose-contraceptive-patch<![CDATA[The FDA approved Viatris' Gwyn Lo, a once-weekly low-dose estrogen (20 mcg) contraceptive patch, based on phase 3 LUMINOUS data showing a Pearl Index of 4.14 pregnancies per 100 woman-years and strong adhesion (98.7% intact). It's approved for women with BMI under 30; common side effects included application-site irritation and intercycle bleeding. Available later in 2026.]]>Fri, 07 Aug 2026 17:56:50 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/global-hepb3-coverage-reaches-81-8-but-regional-gaps-persisthttps://www.ajmc.com/view/global-hepb3-coverage-reaches-81-8-but-regional-gaps-persist<![CDATA[Global third-dose hepatitis B (HepB3) vaccine coverage reached 81.8% in 2023, but persistent gaps in Africa and South Asia threaten WHO elimination goals.]]>Fri, 07 Aug 2026 17:55:51 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/rituximab-matches-ocrelizumab-in-head-to-head-ms-trialhttps://www.ajmc.com/view/rituximab-matches-ocrelizumab-in-head-to-head-ms-trial<![CDATA[The OVERLORD-MS trial finds rituximab matches ocrelizumab in relapsing multiple sclerosis, with similar MRI control, relapses, and safety.]]>Fri, 07 Aug 2026 17:42:01 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/gaps-persist-in-interstitial-lung-disease-carehttps://www.ajmc.com/view/gaps-persist-in-interstitial-lung-disease-care<![CDATA[Experts at the Washington, DC, Pop Health Roundtable discussed delays in ILD diagnosis, multidisciplinary care, antifibrotic therapy, and insurance barriers.]]>Fri, 07 Aug 2026 17:32:04 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/5-novel-fda-approvals-that-signal-a-shift-toward-convenience-driven-carehttps://www.ajmc.com/view/5-novel-fda-approvals-that-signal-a-shift-toward-convenience-driven-care<![CDATA[All from July, these 5 novel therapeutics each claimed a “first” in their category. ]]>Fri, 07 Aug 2026 16:51:52 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/social-risk-weighted-scoring-to-improve-medicare-advantage-star-ratingshttps://www.ajmc.com/view/social-risk-weighted-scoring-to-improve-medicare-advantage-star-ratings<![CDATA[Constrained optimization empirically derived social risk weights that gave equal influence to subgroup performance by dual eligibility and disability in overall contract scores.]]>Fri, 07 Aug 2026 16:00:00 GMTAJMCusAJMC Articles